<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Examples of prophylactic antimicrobial regimens used in patients with immunodeficiency</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Examples of prophylactic antimicrobial regimens used in patients with immunodeficiency</h1>
<div class="graphic"><div class="figure"><div class="ttl">Examples of prophylactic antimicrobial regimens used in patients with immunodeficiency</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Infection to be prevented</td> <td class="subtitle1">First-line regimen</td> <td class="subtitle1">Alternative regimens</td> </tr> <tr class="divider_bottom"> <td><strong><em>Pneumocystis jirovecii</em></strong></td> <td>Sulfamethoxazole-trimethoprim: <ul class="decimal_heading"> <li>Infants &gt;4 weeks of age and children: 5 mg/kg/day orally in 2 divided doses, 3 days/week (based on TMP; maximum 160 mg per dose, 320 mg per day) </li> <li>Adults and adolescents with normal renal function: 160 mg (based on TMP) daily or 3 days/week, or 80 mg (based on TMP) daily </li> </ul> </td> <td>Dapsone: <ul class="decimal_heading"> <li>Infants and children: 2 mg/kg/dose orally once daily (maximum daily dose: 100 mg/day) </li> <li>Adults: 100 mg once daily or 50 mg twice daily </li> </ul> Atovaquone: <ul class="decimal_heading"> <li>1 to 3 months: 30 mg/kg orally once daily </li> <li>4 to 24 months: 45 mg/kg orally once daily </li> <li>&gt;24 months: 30 mg/kg orally once daily </li> <li>Adolescents ≥13 years and adults: 1500 mg orally once daily </li> </ul> Pentamidine: <ul class="decimal_heading"> <li>Children &lt;5 years: 9 mg/kg (maximum dose: 300 mg/dose) inhalation per nebulizer once every 4 weeks </li> <li>Children &gt;5 years, adolescents and adults: 300 mg inhalation per nebulizer once every 4 weeks </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong><em>Staphylococcus </em>spp, gram negative spp</strong></td> <td>Sulfamethoxazole-trimethoprim: <ul class="decimal_heading"> <li>Infants &gt;4 weeks of age and children: 5 mg/kg/day orally in 2 divided doses (based on TMP; maximum 160 mg per dose, 320 mg per day) </li> <li>Adolescents and adults: 160 mg (based on TMP) daily or twice daily </li> </ul> </td> <td>Amoxicillin:* <ul class="decimal_heading"> <li>Children: 10 to 20 mg/kg per day as a single dose or divided twice daily (maximum dose 875 mg per day) </li> <li>Adolescents and adults: 875 mg twice daily </li> </ul> Ciprofloxacin:*<sup>¶</sup> <ul class="decimal_heading"> <li>Children: 10 mg/kg/dose twice daily (maximum dose 500 mg) </li> <li>Adults: 500 mg twice daily </li> </ul> Amoxicillin and clavulanate:* <ul class="decimal_heading"> <li>Children: 20 mg/kg per day as a single dose or divided twice daily (maximum dose 875 mg per day, based on amoxicillin) </li> <li>Adolescents and adults: 875 mg daily (based on amoxicillin) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong><em>Mycoplasma </em>spp, <em>Streptococcus </em>spp</strong></td> <td>Azithromycin: <ul class="decimal_heading"> <li>Children: 5 to 10 mg/kg/dose orally 3 times weekly (maximum dose of 250 mg) </li> <li>Adolescents and adults: 250 mg orally 3 times weekly </li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td><strong>Non-tuberculous mycobacteria</strong></td> <td>Azithromycin: <ul class="decimal_heading"> <li>Children: 20 mg/kg/dose orally once weekly (maximum dose 1200 mg weekly but may be given as 600 mg twice per week if higher doses cause nausea) </li> <li>Adolescents and adults: 1200 mg weekly but may be given as 600 mg twice per week if higher doses cause nausea </li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td><strong><em>Aspergillus </em>spp</strong></td> <td>Itraconazole: <ul class="decimal_heading"> <li>Children: 5 mg/kg/day orally daily (maximum dose 200 mg) </li> <li>Adolescents and adults: 200 mg orally daily </li> </ul> </td> <td>Voriconazole:<sup>Δ</sup> <ul class="decimal_heading"> <li>≤50 kg: 8 mg/kg/dose orally twice daily (maximum dose 350 mg) </li> <li>&gt;50 kg: 4 mg/kg/dose orally twice daily (maximum dose 200 mg) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong><em>Candida </em>spp</strong></td> <td>Fluconazole: <ul class="decimal_heading"> <li>Children: 6 mg/kg orally daily (maximum dose 400 mg) </li> <li>Adolescents and adults: 400 mg orally once daily </li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td><strong>HSV/VZV</strong></td> <td>Acyclovir: <ul class="decimal_heading"> <li>Children &lt;40 kg: 600 mg/m<sup>2</sup>/dose orally 4 times per day </li> <li>Children &gt;40 kg: 800 mg orally 4 times per day </li> <li>Adults: 800 mg orally twice daily </li> </ul> </td> <td> </td> </tr> <tr> <td><strong>CMV</strong></td> <td>Valganciclovir: <ul class="decimal_heading"> <li>Children 1 month to 16 years old: once daily oral dose (mg) = 7 × body surface area × creatinine clearance </li> <li>Adolescents ≥17 years and adults with normal renal function: 900 mg orally once daily </li> </ul> </td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The approach to antimicrobial prophylaxis in patients with various forms of primary immunodeficiency is not standardized. The agents and doses shown in the table are commonly used, but other regimens may also be appropriate.</div><div class="graphic_footnotes">TMP: trimethoprim; spp: species; HSV: herpes simplex virus; VZV: varicella zoster virus; CMV: cytomegalovirus.<br/>* No standard second line as varying strains with varying resistance patterns.<br/>¶ Clinicians should weigh the risks of adverse musculoskeletal effects against the benefits when considering long-term use of fluoroquinolones in children.<br/>Δ Requires drug level monitoring.</div><div class="graphic_reference">References:

<ol>
<li>Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract 2013; 1:573.</li>
<li>Milito C, Pulvirenti F, Cinetto F, et al. Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies. J Allergy Clin Immunol 2019; 144:584.</li>
</ol></div><div id="graphicVersion">Graphic 121854 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
